By Chris Wack

 

ALX Oncology Holdings Inc. said Tuesday it is collaborating with Merck & Co. to evaluate the combination of ALX148 and Keytruda for treating patients with a certain type of head and neck cancer.

Under the terms of the agreement, ALX Oncology will conduct two Phase 2 studies. The first will evaluate the efficacy of ALX148, an investigational next generation CD47 blocker, in combination with Merck's drug to treat patients with PD-L1 expressing metastatic or unresectable, recurrent head and neck squamous cell carcinoma.

The second study will evaluate ALX148, Keytruda and standard chemotherapy to treat patients with metastatic or unresectable, recurrent HNSCC.

ALX Oncology owns worldwide commercial rights to ALX148.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

September 22, 2020 07:51 ET (11:51 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Merck Charts.